Log in to save to my catalogue

Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lym...

Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lym...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_5334ae4bfcbe40568cef6f2f3b2b82a5

Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells

About this item

Full title

Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells

Publisher

Australia: John Wiley & Sons, Inc

Journal title

Clinical & translational immunology, 2024-01, Vol.13 (10), p.e70011-n/a

Language

English

Formats

Publication information

Publisher

Australia: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Paediatric Burkitt's lymphoma (pBL) is the most common childhood non-Hodgkin B-cell lymphoma. Despite the encouraging survival rates for most children, treating cases with relapse/resistance to current therapies remains challenging. CD38 is a transmembrane protein highly expressed in pBL. This study investigates the effectiveness of CD38-targeting...

Alternative Titles

Full title

Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_5334ae4bfcbe40568cef6f2f3b2b82a5

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_5334ae4bfcbe40568cef6f2f3b2b82a5

Other Identifiers

ISSN

2050-0068

E-ISSN

2050-0068

DOI

10.1002/cti2.70011